

## 10<sup>th</sup> INTERNATIONAL CONFERENCE ON CACHEXIA, SARCOPENIA & MUSCLE WASTING

- > Cachexia in Cancer, Heart Failure, COPD, CKD and Stroke
- > Sarcopenia, Frailty and the Dymobility Syndrome
- > Pathophysiology and Epidemiology of Muscle Wasting
- > Body Composition Assessments
- > Screening, Diagnostic and Management
- > Special Populations
- > Clinical Trial Data

Rapid fire abstracts sessions

Young investigator awards

Late-breaking research and clinical abstract deadline: 30 September, 2017

Plenty of time for discussion

# ROME

8-10 DECEMBER 2017



Dear Colleague,

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to invite you to attend its first Updates Programme on Cachexia, Sarcopenia and Wasting Diseases that will be held on December 8-10, 2017, in Rome, Italy.

As an international and multidisciplinary organization, the SCWD seeks to further research on cachexia, sarcopenia and muscle wasting in order to bring practical solutions to healthcare teams worldwide.

Since the first cachexia conference that took place in Berlin in 2000, over 2000 physicians from over 25 countries have attended our educational sessions.

We expect this SCWD conference in 2017 to be a unique forum for all medical professionals dealing with muscle wasting in their disciplines and we look forward to meeting you in Rome.

We have already more than 180 abstracts and that is very encouraging.

Looking forward to meeting you in Rome.

Yours sincerely,  
John E. Morley  
Stefan D. Anker

#### **CHAIRMEN:**

John E. Morley, St. Louis, MO, USA  
Stefan D. Anker, Berlin, Germany

#### **INTERNATIONAL SCIENTIFIC COMMITTEE:**

Stefan D. Anker (President) – Berlin, Germany  
John E. Morley – St. Louis, USA  
William J. Evans – Durham, USA  
Akio Inui – Kobe, Japan  
Josep M. Argiles – Barcelona, Spain  
Filippo Rossi-Fanelli – Rome, Italy  
Vickie E. Baracos – Edmonton, Canada  
Andrew Coats, Melbourne, Australia and Warwick, UK

Wolfram Doehner – Berlin, Germany  
Luigi Ferrucci – Baltimore, USA  
David J. Glass – Boston, USA  
Aminah Jatoi – Rochester, USA  
Kamyar Kalantar-Zadeh – Torrance, USA  
Maurizio Muscaritoli – Rome, Italy  
Florian Strasser – St. Gallen, Switzerland  
Stephan von Haehling – Göttingen, Germany

## MORNING

**8:00-8:45** Special sessions: pre-registrations only

### Statistical Seminar

**CHAIRS:** Jennifer Le-Rademacher, USA  
Jeffrey Crawford, USA

### Ken Fearon Career Café – Meet the Mentor

Coordinated by Mitja Lainscak, Slovenia

**A 9:00-10:50** Opening SESSION 1

**CHAIRS:** Stefan Anker, Germany  
Maurizio Muscaritoli, Italy  
Filippo Rossi-Fanelli, Italy

Welcome by the Chairs

### “Hippocrates” clinical science key note lecture: Role of mitochondria in age-related muscle impairment

Luigi Ferrucci, USA

### Frailty in 2017

Bruno Vellas, France

### Sex differences in cachexia, sarcopenia and wasting disorders

James Carson, USA

### Research gaps from the NCI consensus

Joanne Elena, USA

### A payer perspective on cachexia and sarcopenia

Bette Caan, USA

**10:50-11:20** Coffee break

**B 11:20-13:00** Opening SESSION 2

**CHAIRS:** Josep Argiles, Spain  
Andrea Bonetto, USA

### “Prometheus” basic science key note lecture

William Evans, USA

### News from proteomic and gene expression data related to aging and cachexia

H. Alexander Ehardt, Ireland

### Cause of death in sarcopenia & cachexia

Stefan Anker, Germany

### Metabolic modulation by nutrients

Maurizio Muscaritoli, Italy

### Precision medicine for cachexia

John Morley, USA

**13:15-14:15** Lunch seminar(s)

## AFTERNOON

**14:30-16:00**

2 PARALLEL SESSIONS

### C Clinical Track Translating sarcopenia research across diseases

**CHAIR:** Zudin Puthuchear, UK

#### Skeletal muscle ammonia metabolism in non-hepatological disease

Srinivasan Dasarathy, USA

#### Kidney dysfunction as a contribution to muscle wasting in chronic illness

Giacomo Garibotto, Italy

#### Separating inflammation and deconditioning as contributors to muscle wasting in COPD

Paul Greenhaff, UK

#### Molecular signaling homology across muscle wasting conditions

Dario Coletti, Italy

#### Sarcopenia in 2017 – what is new?

Francesco Landi, Italy

**16:00-17:00** Coffee break & science

**16:05-16:55** Poster Viewing Session 1

**16:10-16:50** Rapid Fire Abstract Session 1

**CHAIRS:** Andrea Bonetto, Italy  
David Waning, USA

**17:00-18:30**

2 PARALLEL SESSIONS

### E Clinical Track Biological versus numerical aging

**CHAIRS:**

#### DNA methylation and the biological clock

TBD

#### Frailty scoring: biological aging phenotypes in the critically ill survivors

Zudin Puthuchear, UK

#### Relationship between aging and physiological function

Stephen Harridge, UK

#### Nutritional status and satiety and the interaction with biological ageing

Alessandro Laviano, Italy

#### Panel discussion

### F Basic track Tumor-secreted factors, cytokines and concepts of cachexia development

**CHAIRS:** Didier Attaix, France  
Giovanni Mantovani, Italy

#### Metabolic regulators of cachexia in cancer

Pankaj Singh, USA

#### New insights on cancer cachexia

Denis Guttridge, USA

#### The muscle gp130 receptor's role for cancer-induced anabolic resistance: therapeutic implications for improving cancer survival

James Carson, USA

#### Mechanisms of muscle atrophy and hypertrophy

David Glass, USA

#### MIC-1 / GDF-15

Samuel Breit, Australia

**18:30-19:30** Welcome reception & poster viewing

## MORNING

7:45-8:45 Morning symposia

7:45-8:45 Joint session of SCWD & ESPEN

8:00-8:45 Special sessions: pre-registrations only

### Statistical Seminar

**CHAIRS:** Jennifer Le-Rademacher, USA  
Jeffrey Crawford, USA

### Ken Fearon Career Café – Meet the Mentor

Coordinated by Mitja Lainscak, Slovenia

9:00-10:30

### 3 PARALLEL SESSIONS

#### G Recent developments and updates on CT imaging for body composition analysis

**CHAIRS:** Andrew Coats, UK  
Joanne Elena, USA

#### Methodological standards of CT imaging and its use as endpoint in clinical trials

Vickie Baracos, Canada

#### Clinical practice of anti-cancer treatment dose adaption by muscle mass data

Florian Strasser, Switzerland

#### CT based muscle radiodensity as prognostic marker

Sami Antoun, France

#### CT based assessment of muscle mass in clinical trials: the reality check and industry view

TBD

#### CT imaging in phase 2/3 trials – what the regulators expect to see?

TBD

#### Panel discussion

#### H How to assess muscle mass and function using non-imaging techniques

**CHAIRS:** Stephan von Haehling, Germany  
William Evans, USA

#### The need for accurate assessment of body composition in infants and children

Daniel Marks, USA

#### The D3-creatine dilution method: methodology & new data

Eric Orwoll, USA

#### MrOs: Longitudinal observational trial in older men – body composition and outcomes

Peggy Cawthon, USA

#### SPRINT-T – update 2017

Roberto Bernabei, Italy

#### Panel discussion

#### I Young investigators awards session

Clinical & Basic

**CHAIRS:** Luigi Ferrucci, USA  
Alessandro Laviano, Italy

**Judges:** Giovanni Mantovani, Italy  
Teresa Zimmers, USA  
Samuel Breit, Australia

10:30-11:30 Coffee break & science

10:35-11:25 Poster Viewing Session 2

10:40-11:20 Rapid Fire Abstract Session 2

11:30-13:00

### 3 PARALLEL SESSIONS

#### J Muscle loss in liver diseases

**CHAIRS:** TBD  
TBD

#### Epidemiology and clinical significance of sarcopenia in liver cirrhosis

Mathias Plauth, Germany

#### Significance of sarcopenia and sarcopenic obesity in fatty liver

Manuela Merli, Italy

#### Molecular mechanisms of sarcopenia in liver cirrhosis

Michela Giusto, Italy

#### Role of MiF in muscle wasting

Steven Olde Damink, The Netherlands

#### Treatment approaches for muscle wasting in liver cirrhosis

Srinivasan Dasarathy, USA

#### K Cachexia: not just muscle

**CHAIRS:** James Carson, USA  
Jochen Springer, Germany

#### The bone-muscle cross-talk

David Waning, USA

#### Adipogenic drive in cancer-induced muscle wasting

Paola Costelli, Italy

#### Energy metabolism, mitochondria and cachexia in COPD

Anemie Schols, The Netherlands

#### Metabolic regulation of fat in cancer cachexia

Stefan Herzig, Germany

#### Protecting fat to gain muscle – a possible new therapeutic concept?

TBD

#### L Nutritional approaches to combat sarcopenia & cachexia

**CHAIR:** Nicolaas Deutz, USA

#### Malnutrition and Cachexia in cancer patients at first medical oncology visit

Maurizio Muscaritoli, Italy

#### Micronutrients in sarcopenia and age-related physical decline

Jerome Feige, Switzerland

#### Interaction exercise and nutrition in sarcopenia

Roger Fielding, USA

#### The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly

Pol Grootswagers, The Netherlands

#### Proteins to treat sarcopenia

Jürgen Bauer, Germany

#### Trial experience in wasting disorders using nutritional approaches

Jann Arends, Germany

13:15-14:15 Lunch seminar(s)

AFTERNOON

14:30-16:00

3 PARALLEL SESSIONS

**M Models of cachexia**

*CHAIRS:* Stefan Herzig, Germany  
Jochen Springer, Germany

**Human xenografts as a suitable model for studying cancer cachexia**

Andrew Judge, USA

**Modeling cachexia: the impact of anti-neoplastic therapy**

Andrea Bonetto, USA

**Experimental models for aging and sarcopenia**

TBD

**New experimental model of cancer cachexia & kidney disease**

Dan Marks, USA

**Large animal models of human cachexia: update 2017**

Lisa Freeman, USA

**N Cachexia at its worst**

*CHAIRS:* Vicky Baracos, Canada  
Stephan von Haehling, Germany

**Diagnostic criteria for the classification of cancer-associated weight loss**

Egidio Del Fabbro, USA

**Wasting of muscle involved in swallowing and mastication**

Florian Strasser, Switzerland

**Diagnosis and management of oropharyngeal dysphagia**

Pere Clavé, Spain

**Treating shortness of breath in advanced cancer cachexia – the muscle hypothesis**

Andrew Coats, UK

**Palliative care and anabolic therapies**

Aminah Jatoi, USA

**O Targeting skeletal muscle – from research to clinical development**

*CHAIRS:* TBD  
TBD

**Biopsies of skeletal muscle – a source of new understanding**

Volker Adams, Germany

**Muscle satellite cells**

Mariz Vainzof, Brazil

**Diabetes and muscle**

Leocadio Rodríguez Mañas, Spain

**Gene therapy approaches to treat cancer cachexia**

Paul Gregorevic, Australia

**Cachexia & sarcopenia – how to develop and get approved drugs there**

Giuseppe Rosano, UK

16:00-17:00

Coffee break & science

16:05-16:55

Poster Viewing Session 3

16:10-16:50

Rapid Fire Abstract Session 3

17:00-18:30

3 PARALLEL SESSIONS

**P Rehabilitation in advanced elderly cancer patients with cachexia**

*CHAIRS:* Paolo Bossi, Italy  
Florian Strasser, Switzerland

**Muscle of the elderly and physical activity: balancing over- and undertreatment**

Francesco Landi, Italy

**Exercise training as an effective tool to improve cancer-induced wasting muscle**

Fabio Penna, Italy

**Current trials in cancer studying physical activity, endurance and strength training**

Vivianne Hess, Switzerland

**Rehabilitative-geriatric interventions in elderly advanced cancer patients: who will respond?**

Pierre Soubeyran, France

**Anabolic interventions in men and women: is there emerging evidence?**

Hans Wildiers, Belgium

**What can cancer cachexia rehabilitation trials learn from critical care rehabilitation?**

Linda Denehy, Australia

**Q Potential treatments for muscle wasting and cachexia**

*CHAIR:* Volker Adams, Germany  
Marco Sandri, Italy

**MEK inhibitors as potential tools to improve cancer-induced muscle wasting**

Erin Talbert, USA

**MAGIC-F1 modulations to improve myogenesis**

Maurilio Sampaolesi, Italy

**Irisin, vitamin D and muscle-bone interactions**

Maria Grano, Italy

**Drugs modifying catabolic/anabolic balance: ACE inhibitors + beta-blockers**

Mitja Lainscak, Slovenia

**What else is new – update from the big pharma pipeline**

David Glass, Switzerland

**R Muscle wasting and cachexia in chronic illnesses – update 2017**

*CHAIRS:* Annemie Schols, The Netherlands  
Giacomo Garibotto, Italy

**COPD**

TBD

**Chronic heart failure**

Stephan von Haehling, Germany

**Chronic kidney disease failure**

Robert Mak, USA

**Stroke**

Wolfram Doehner, Germany

**Cancer**

Jeffrey Crawford, USA

7:45-8:45 <b>Morning Symposia</b>	
7:45-8:45 <b>Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)</b>	
9:00-10:15 <b>2 PARALLEL SESSIONS</b>	
<p><b>S</b> <b>Imaging methods for assessing muscle mass</b></p> <p><i>CHAIRS:</i> Vickie Baracos, Canada Steven Heymsfield, USA</p> <p><b>Body impedance</b> Maria-Christina Gonzalez, Brazil</p> <p><b>Cross-sectional: CT or MRI</b> Vickie Baracos, Canada</p> <p><b>Quadriceps contractile volume by MRI</b> Thomas Maden-Wilkinson, UK</p> <p><b>Ultra-sound methods</b> Thiago Gonzalez Barbosa-Silva, Brazil</p> <p><b>Panel discussion</b></p>	<p><b>T</b> <b>Frailty &amp; sarcopenia – update 2017</b></p> <p><i>CHAIRS:</i> Bruno Vellas, France John Morley, USA</p> <p><b>The physical frailty phenotype</b> TBD</p> <p><b>Treatment trials for frailty</b> TBD</p> <p><b>Validating SARC-F</b> Jean Woo, Hong Kong</p> <p><b>The role of T2DM in the development of sarcopenia and frailty</b> Theodore Malmstrom, USA</p> <p><b>Treating sarcopenia</b> Tommy Cederholm, Sweden</p>
10:15-11:15 <b>Coffee break &amp; science</b>	
10:20-11:10 <b>Poster Viewing Session 4</b>	
11:15-12:45 <b>2 PARALLEL SESSIONS</b>	
<p><b>U</b> <b>Clinical trials in progress</b></p> <p><i>CHAIRS:</i> Aminah Jatoi, USA Andrew Coats, UK</p> <p><b>Re-testing fish oil for cachexia</b> TBD</p> <p><b>Eccentric exercise for rheumatoid arthritis patients with muscle wasting</b> Patrick Lacarin, France</p> <p><b>Peptamen for weight loss</b> Andrew Hendifar, USA</p> <p><b>Cannabis for cancer-associated weight loss</b> Moran Grinberg, Israel</p> <p><b>Sildenafil for cholangiocarcinoma or pancreas cancer: rationale and study design</b> Melinda Sheffield Moore, USA</p>	<p><b>V</b> <b>Intensive care unit myopathy: molecular signals and clinical observations</b></p> <p><i>CHAIRS:</i> William Evans, USA</p> <p><b>Introduction and historical data: nutritional intervention strategies</b> Nicolaas Deutz, USA</p> <p><b>ICU associated muscle wasting: molecular signals &amp; contractile function in animal models</b> TBD</p> <p><b>Inflammation as a trigger for rapid loss of muscle: pre-clinical and clinical data</b> Paul Greenhaff, UK</p> <p><b>Molecular signals in skeletal muscle from ICU patients: the role of GDF-15</b> Mark Griffiths, UK</p> <p><b>Clinical experience: treating muscle wasting in the ICU</b> TBD</p>
12:45-13:15 <b>Coffee break</b>	
13:15-14:45 <b>2 PARALLEL SESSIONS</b>	
<p><b>W</b> <b>Late breaking clinical trials &amp; trial updates</b></p> <p><i>CHAIRS:</i> Andrew Coats, UK Stefan Anker, Germany</p>	<p><b>X</b> <b>Anorexia of disease, fasting metabolism and clinical outcome</b></p> <p><i>CHAIR:</i> Filippo Rossi-Fanelli, Italy</p> <p><b>Targeting the adipose tissue in cancer cachexia</b> Josep Argiles, Spain</p> <p><b>Lessons from fasting metabolism: is there any benefit of anorexia during disease?</b> Alessandro Laviano, Italy</p> <p><b>Gut-brain axis: role of microbiota in anorexia of disease</b> Serguei Fetissov, France</p> <p><b>Filling the caloric gap during disease: does it ameliorate clinical outcomes?</b> TBD</p> <p><b>Gastrointestinal hormones: a suitable target to treat anorexia of disease?</b> Jessie Elliott, Ireland</p>
14:45-15:45 <b>Highlights of the congress</b>	
<i>CHAIRS:</i> Stefan Anker, Germany - Maurizio Muscaritoli, Italy - Annemie Schols, The Netherlands	
<b>Basic science &amp; pathophysiology</b> Annemie Schols, The Netherlands	
<b>Body composition</b> Steven Heymsfield, USA	
<b>Sarcopenia</b> Stephan von Haehling, Germany	
<b>Cachexia in chronic illness</b> TBD	
<b>Nutrition treatment</b> Roger Fielding, USA	
<b>Treatment of cachexia</b> Andrew Coats, UK	
<b>Awards Ceremony</b>	
Best Poster Award • Young Investigators Award • Trainee Poster Award	

## EDUCATIONAL OBJECTIVES:

Following this activity, the audience will be able to:

1. Review the latest information about the pathophysiology of muscle wasting and its epidemiology.
2. Screen for and diagnose cachexia, sarcopenia, frailty and dysmobility resulting from the following diseases or chronic conditions: cancer, cardiovascular disease, COPD, CKD, dementia/Alzheimer's disease, diabetes, infectious diseases, stroke and aging.
3. Develop appropriate management programs for patients across the continuum of care.

## TARGET AUDIENCE:

Internists, oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses.

Organization

**MEDED GLOBAL SOLUTIONS**

27, rue Raffet, 75016 Paris, France

Tel: +33 (0)1 44 01 51 81

Fax: +33 (0)1 44 01 51 80

E-mail: [scwd@mededgs.com](mailto:scwd@mededgs.com)

[www.cachexia.org](http://www.cachexia.org)



**Online registration:**

[www.cachexia.org](http://www.cachexia.org)

### DATES

Friday, December 8, 2017  
to Sunday, December 10, 2017

### ABSTRACTS

Deadline for late-breaking research  
and clinical trial abstracts is  
September 30, 2017.

All abstracts will be published  
in the Journal of Cachexia,  
Sarcopenia and Muscle (JCSM).

### VENUE

**Sheraton Roma Hotel  
& Conference Center**  
Viale Del Pattinaggio, 100  
Rome, 00144, Italy  
Tel: +39 (06) 54531

> Official language: English